Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chris Rombach
09.16.22 -- A CTO's Journey Into Continuous Biomanufacturing
With Chris Hwang, chief technology officer, Transcenta Holding Ltd. At a recent Evaluating BioPharma virtual event, moderator John Bonham-Carter asked Chris Hwang, chief technology officer at Transcenta Holding Ltd., about Chris’s journey and experiences with continuous bioprocessing thus far in his career. By Matthew Pillar, editor, FDA-ordered clinical holds are on the rise, and biologics INDs are driving them.
03.15.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Deanna Mudie, Ph.D., Lonza With so many different media available that vary widely in properties and composition, it is important to know how to select a dissolution media that can effectively test formulation robustness. Article | By Chris Rombach, Asahi Kasei Bioprocess The rapidly growing market for oligonucleotide manufacturing represents an opportunity for investors and pharma companies that wish to produce novel pharmaceutical products and therapies.
5 Biggest Trends Of Oligonucleotide Manufacturing In 2022
By Chris Rombach, Vice President of Sales and Marketing, Asahi Kasei Bioprocess America The oligonucleotide manufacturing industry is experiencing significant growth, with numerous pharmaceutical companies investing in the development of novel pharmaceutical products and therapies. Synthetic oligonucleotides have already been used extensively, resulting in the approval of several oligonucleotide drugs by the FDA, with many more in development.
02.04.22 -- Be Better Prepared With Your New Continuous Manufacturing Perfusion System Than We Were
Article | By Chris Rombach, Asahi Kasei Bioprocess Data analytics from unit operations and throughout the processing flow continuum allow for fewer batch comparisons, thereby decreasing development timelines and cost to market. Article | By Paul Magreta, CHIRON Recombinant Proteins The biopharma industry has been challenged to discover and develop new diagnostic tests, treatments, and vaccines to help resolve the pandemic. Learn how one CDMO embraces the challenge.
Driving Efficiency And Ingenuity With An OPC Platform
By Chris Rombach, VP Sales & Marketing, Asahi Kasei Bioprocess America The regulatory approval of several oligonucleotides over the past five years – combined with the recent headlines around rapid COVID-19 vaccine development – has created significant interest in the oligonucleotide (DNA/RNA) segment of the scientific industry.
Driving Efficiency And Ingenuity With An OPC Platform
By Chris Rombach, VP Sales & Marketing, Asahi Kasei Bioprocess America The regulatory approval of several oligonucleotides over the past five years – combined with the recent headlines around rapid COVID-19 vaccine development – has created significant interest in the oligonucleotide (DNA/RNA) segment of the scientific industry.
02.19.20 -- The Perilous Development Of A Potential Biologic Blockbuster
Newsletter | February 19, 2020 Sponsor Bioanalytical Labs Market Dynamics And Service Provider Performance (4th Edition) For sponsors: Evaluate your lab selection process. Explore new providers and understand how they have performed for industry peers. Compare your company’s bioanalytical lab outsourcing philosophy to that of the broader industry. For bioanalytical labs: Learn how your company performs against competitors.
02.12.20 -- Valentine's Day Heartbreak: How To Let Your (Underperforming) CMO Partner Go
Newsletter | February 12, 2020 02.12.20 -- Valentine's Day Heartbreak: How To Let Your (Underperforming) CMO Partner Go Discuss Downstream Purification Strategies At 2020 Events BPI Asia, February 26 to 28, Kyoto, Japan. Attend the Poster Session on Nuvia aPrime 4A and request resin samples BPI West, March 9 to 12, Santa Clara Convention Center. Visit Booth 506 and attend the Boehringer Ingelheim Site Tour and Process Development Seminar on March 9 ACS BIOT, March 22 to 26, Philadelphia, PA.
Boosting Profitability with Single-Use Powder Transfer
Many biopharmaceutical manufacturers are implementing single-use containment for transfer of media and buffer materials to prevent feedstock contamination and promote worker safety. But the type of containment system used can have a significant impact on productivity and profitability. Equipment should be evaluated and chosen carefully.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chris
Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack